Edward M. Bednarczyk PharmD, FCCP, FAPhA
Pharmaceutical & Regulatory Advisor
OptiMed Technology, INC. Buffalo NY
Director, Center for Health Outcomes, Pharmacoinformatics and Epidemiology
Chair, Clinical Associate Professor, Department of Pharmacy Practice, University at Buffalo
Edward M. Bednarczyk PharmD, FCCP, FAPhA
Professional Summary:
Dr. Bednarczyk’s research interests are focused to the application of molecular imaging techniques such as positron emission tomography (PET) to assessing drug effects, including the study of migraine headache where we have looked at treatment as well as induction of headache. We have also had recent work looking at opiate receptors in the human brain using 11C-carfentanil, a radiopharmaceutical that binds to the mu opiate receptor.
Dr. Bednarczyk's research had included a study on the regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine.
The characteristics of positron emitting radio nuclides often make them ideal tracers for measuring drug effects. This includes the labeling drugs with PET radio nuclides such as C-11, or F-18. These nuclides allow for creation of labeled drugs nearly identical to their unlabelled counterparts. We have also used ³workhorse¹ radiopharmaceuticals such as FDG in a variety of settings ranging from measuring the uptake of glucose into white blood cells, to oral administration of this radiopharmaceutical, to application in the assessment of response to drugs in dementia. Other research areas include migraine headache, and neuroreceptor binding studies.
Education and Training:
-
Cardiovascular Clinical Pharmacology Research, University Hospitals of Cleveland/Case Western Reserve University (1989)
-
PharmD, Pharmacy, Medical University of South Carolina, College of Pharmacy (1987)
-
Buffalo General Hospital (1985)
-
BS, The State University of New York at Buffalo, School of Pharmacy (1984)
Professional Memberships:
-
American Association of Colleges of Pharmacy (2008–present)
-
Society for Nuclear Medicine, Eastern Great Lakes Chapter SNM (1995–present)
-
American Headache Society (1995–present)
-
American Society for Clinical Pharmacology and Therapeutics (1987–2014)
-
Society for Nuclear Medicine (1987)
-
American College of Clinical Pharmacy (1985–present)
-
American Society of Health System Pharmacists (1985)
-
American Pharmacists Association (1984–present)
-
Christian Pharmacists Fellowship International
-
National Headache Foundation
-
New York State Chapter of the American College of Clinical Pharmacy
-
Society of Nuclear Imaging in Drug Development
-
Academy for Molecular Imaging (Society of Nuclear Imaging in Drug Development)
-
International Headache Society
-
American Heart Association
-
American Medical Writers Association
Journal Articles:
-
Sellick J, Mergenhagen K, Morris L, Feuz L, Horey A, Risbood V, Wojciechowski A, Ruh C, Bednarczyk E, Conway E, Ott M, Bednarczyk EM. Fluoroquinolone-Related Neuropsychiatric Events in Hospitalized Veterans. Psychosomatics. 2018; 59(3).
-
Hershey LA, Bednarczyk EM. Treatment of headache in the elderly. Curr Treat Options Neurol. 2013; 15(1).
-
Smith DM; Hyland AJ; Rivard C; Bednarczyk EM; Brody PM; Marshall JR. Tobacco sales in pharmacies: a survey of attitudes, knowledge and beliefs of pharmacists employed in student experiential and other worksites in Western New York. BioMed Central Research Notes. 2012; 5.
-
Prescott GM; Venci JV; Bednarczyk EM. An Advanced Pharmacy Practice Experience in Spirituality and Ethics at a Secular School. Christianity and Pharmacy. 2012; 15.
-
Brazeau GA, Meyer SM, Belsey M, Bednarczyk EM, Bilic S, Bullock J, DeLander GE, Fiese EF, Giroux SL, McNatty D, Nemire R, Prescott WA, Traynor AP. Preparing pharmacy graduates for traditional and emerging career opportunities. Am J Pharm Educ. 2009; 73(8).
-
Kassab MY; Oakhtar O; Wack DS; Bednarczyk EM. Resting brain glucose uptake in headache free migraineurs. Headache. 2009; 49.
-
Constantinescu RA; Brown SE; Lorenzo BJ; Ravena B; Kieburtz K; McDermott MP; DiCenzo R; deBlieck EA; Hyson HC; Beal MF; Bednarczyk EM; Bogdanov M; Metakis MJ. Randomized Study of the Bioavailability of Different Formulations of Coenzyme Q10 (Ubiquinone). J Clin Pharmacol. 2007; 47.
-
Constantinescu R, McDermott MP, Dicenzo R, de Blieck EA, Hyson HC, Beal MF, Bednarczyk EM, Bogdanov M, Metakis LJ, Browne SE, Lorenzo BJ, Ravina B, Kieburtz K. A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone). J Clin Pharmacol. 2007; 47(12).
-
Kassab MY; Majid A; Bakhtar O; Farooq MU; Patel K; Bednarczyk EM. Transcranial Doppler measurements in migraine and nitroglycerin headache. J Headache Pain. 2007; 8.
-
Kassab MY, Majid A, Bakhtar O, Farooq MU, Patel K, Bednarczyk EM. Transcranial Doppler measurements in migraine and nitroglycerin headache. J Headache Pain. 2007; 8(5).
-
Kassab MY, Majid A, Farooq MU, Azhary H, Hershey LA, Bednarczyk EM, Graybeal DF, Johnson MD. Transcranial Doppler: an introduction for primary care physicians. J Am Board Fam Med. 2007; 20(1).
-
Kassab MY; Majid A; Farooq MU; Azhary H; Bednarczyk EM; Graybeal DF; Johnson M. Transcranial Doppler: An Introduction for the Primary Care Physician. JABFM. 2007; 20.
-
Giglio P, Bednarczyk EM, Weiss K, Bakshi R. Syncope and head CT scans in the emergency department. Emerg Radiol.. 2005; 12(1 - 2).
-
Giglio P, Bednarczyk EM, Weiss K, Bakshi R. Syncope and head CT scans in the emergency department. Emerg Radiol. 2005; 12(1-2).
-
Zubeldia JM, Bednarczyk EM, Baker JG, Nabi HA. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases. Cancer Biother Radiopharm. 2005; 20(4).
-
Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, Johnson S. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis.. Dement Geriatr Cogn Disord. 2004; 17(Sup1).
-
Bednarczyk EM, Wack DS, Kassab M, Burch K, Trinidad KS, Haka MS, Gona JM. Brain blood flow in the nitroglycerin (GTN) model of migraine: measurement using positron emission tomography and transcranial Doppler.. Cephalalgia. 2002; 22(9).
-
Mayer D, Bednarczyk EM. Interaction of colony-stimulating factors and fluorodeoxyglucose f(18) positron emission tomography. Ann Pharmacother. 2002; 36(11).
-
Coleman RE, Bednarczyk EM, Chilton H. Positron emission tomography: from production and distribution to drug research and clinical applications. J Am Pharm Assoc (Wash). 2000; 40(5 Sup).
-
Bednarczyk EM, Remler B, Weikart C, Nelson AD, Reed RC. Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache. Neurology. 1998; 50(6).
-
Bednarczyk EM, Kyllonen KS. Establishment of a drug information service on a public-access computer bulletin board. Ann Pharmacother. 1995; 29(12).
-
Gardner SF, Green JA, Bednarczyk EM, Farnett L, Miraldi F. Principles and clinical applications of positron emission tomography. Am J Hosp Pharm. 1992; 49(6).
-
Berridge MS, Adler LP, Nelson AD, Cassidy EH, Muzic RF, Bednarczyk EM, Miraldi F. Measurement of human cerebral blood flow with [15O]butanol and positron emission tomography. J Cereb Blood Flow Metab. 1991; 11(5).
-
Munger MA, Rutherford WF, Anderson L, Hakki AI, Gonzalez FM, Bednarczyk EM, Emmanuel G, Weed SG, Panacek EA, Green JA. Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Crit Care Med. 1990; 18(5).
-
Bednarczyk EM, Rutherford WF, Leisure GP, Munger MA, Panacek EA, Miraldi FD, Green JA. Hyperventilation-induced reduction in cerebral blood flow: assessment by positron emission tomography. DICP. 1990; 24(5).
-
Green JA, Munger MA, Reed RC, Bednarczyk EM. Pharmacy practice acts: are they stifling professional growth? Am Pharm. 1989; NS29(12).